Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
Fludarabine and 1-beta-D-arabinofuranosylcytosine (ara-C) are effective nucleoside analogues for the treatment of leukemias when used as single agents or together. Recent trials of the fludarabine and ara-C therapy with or without growth factors suggested an improved clinical response by combining fludarabine and ara-C. The activity of these antimetabolites depends on their phosphorylation to the respective triphosphates, F-ara-ATP and ara-CTP. The principal mechanism through which these triphosphates cause cytotoxicity is incorporation into DNA and inhibition of further DNA synthesis. A model system of DNA primer extension on a defined template sequence was used to quantitate the consequences of incorporation of one or two analogues by human DNA polymerase alpha (pol alpha). The template (31-mer) was designed so that DNA pol alpha incorporated six deoxynucleotides (alternately G and T) on the 17-mer primer, followed by insertion of an A and then a C. The primer was then elongated with G and T to the full-length product. The apparent Kms of DNA pol alpha to incorporate these analogues (0. 053 and 0.077 microM, respectively) were similar to the Km for dCTP (0.037 microM) and dATP (0.044 microM), suggesting that the enzyme recognized these analogues and incorporated them efficiently on the growing DNA primer. The velocity of extension (Vmax) of these primers ranged between 0.53 and 0.77%/min when normal nucleotides were present. Once inserted at the 3'-terminus, F-ara-AMP or ara-CMP were poor substrates for extension. However, in reactions lacking dCTP and dATP and with high concentrations of ara-CTP, ara-CMP was inserted by pol alpha after incorporation of the F-ara-AMP residue. This tandem incorporation of the two analogues resulted in almost complete inhibition (99.3%) of further extension of the primer. In the presence of competing deoxynucleotides, each analogue resulted in a dose-dependent inhibition of DNA synthesis. When present together, inhibition of the primer elongation was more than additive at low concentrations of analogue triphosphates. Based on these results and the intracellular pharmacokinetics of ara-CTP and F-ara-ATP in leukemia blasts, we propose a pharmacodynamic model to explain interactions between these analogues during combination chemotherapy.
Gandhi
V
V
Department of Clinical Investigation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Huang
P
P
Chapman
A J
AJ
Chen
F
F
Plunkett
W
W
D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D001088:Arabinonucleotides / Q000493:pharmacokinetics*; D001482:Base Composition; D001483:Base Sequence; D004256:DNA Polymerase I / Q000378:metabolism*; D017931:DNA Primers; D006801:Humans; D007700:Kinetics; D013379:Substrate Specificity; D013698:Templates, Genetic; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives* / Q000378:metabolism
D000970:Antineoplastic Agents; D001088:Arabinonucleotides; D017931:DNA Primers; D001084:Vidarabine Phosphate; C000101:ara-ATP; C034957:2-fluoro-araATP; D004256:DNA Polymerase I